Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Pharmacol Exp Ther ; 320(3): 1171-7, 2007 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-17138865

RESUMEN

Substance P (SP) and calcitonin gene-related peptide (CGRP) are well established mediators of inflammation. Therefore, inhibition of the biosynthesis of these neuropeptides is an attractive potential strategy for pharmacological intervention against a number of inflammatory diseases. The final step in the biosynthesis of SP and CGRP is the conversion of their glycine-extended precursors to the active amidated peptide, and this process is catalyzed by sequential action of the enzymes peptidylglycine alpha-monooxygenase (PAM) and peptidylamidoglycolate lyase. We have demonstrated previously that 4-phenyl-3-butenoic acid (PBA) is a PAM inhibitor, and we have also shown that in vivo inhibition of serum PAM by PBA correlates with this compound's ability to inhibit carrageenan-induced edema in the rat. Here we demonstrate the ability of PBA to inhibit all three phases of adjuvant-induced polyarthritis (AIP) in rats; this represents the first time that an amidation inhibitor has been shown to be active in a model of chronic inflammation. We recently introduced 5-(acetylamino)-4-oxo-6-phenyl-2-hexenoic acid (AOPHA) as one of a new series of mechanism-based amidation inhibitors. We now report for the first time that AOPHA and its methyl ester (AOPHA-Me) are active inhibitors of serum PAM in vivo, and we show that AOPHA-Me correspondingly inhibits carrageenan-induced edema in rats in a dose-dependent manner. Neither PBA nor AOPHA-Me exhibits significant cyclooxygenase (COX) inhibition in vitro; thus, the anti-inflammatory activities of PBA and AOPHA-Me are apparently not a consequence of COX inhibition. We discuss possible pharmacological mechanisms that may account for the activities of these new anti-inflammatory compounds.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Artritis Experimental/tratamiento farmacológico , Caproatos/uso terapéutico , Edema/tratamiento farmacológico , Ésteres/uso terapéutico , Ácidos Grasos Monoinsaturados/uso terapéutico , Neuropéptidos/metabolismo , Adyuvantes Inmunológicos , Animales , Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/farmacología , Artritis Experimental/metabolismo , Caproatos/química , Caproatos/farmacología , Ciclooxigenasa 1/sangre , Ciclooxigenasa 1/metabolismo , Ciclooxigenasa 2/sangre , Ciclooxigenasa 2/metabolismo , Relación Dosis-Respuesta a Droga , Edema/metabolismo , Ésteres/química , Ésteres/farmacología , Ácidos Grasos Monoinsaturados/química , Ácidos Grasos Monoinsaturados/farmacología , Fosfolipasas A2 Grupo II , Humanos , Técnicas In Vitro , Masculino , Estructura Molecular , Fosfolipasas A/metabolismo , Ratas , Ratas Sprague-Dawley , Nervio Ciático/metabolismo , Sustancia P/metabolismo
2.
Eur J Pharmacol ; 471(2): 121-8, 2003 Jun 20.
Artículo en Inglés | MEDLINE | ID: mdl-12818699

RESUMEN

Responding of rats was maintained under a 120-response fixed ratio (FR) schedule of food delivery, and animals received individual and combined injections of N-methyl-D-aspartic acid (NMDA), phencyclidine hydrochloride, (+)-MK-801 hydrogen maleate (MK-801), (+/-)-2-amino-5-phosphonopentanoic acid (AP5), 7-chlorokynurenic acid (7CK), ifenprodil tartrate, N(G)-nitro-L-arginine methyl ester hydorchloride (L-NAME), 7-nitroindazole, aminoguanidine hemisulfate, L-arginine, molsidomine, sodium nitroprusside, and 8-(diethylamino)octyl 3,4,5-trimethoxybenzoate hydrochloride (TMB-8). Behavioral suppression after NMDA was completely and dose-dependently reversed by MK-801, phencyclidine, AP5, and aminoguanidine; partially and dose-dependently attenuated by molsidomine, ifenprodil, and 7CK; and not attenuated at all by L-NAME, 7-nitroindazole, or TMB-8. These findings suggested that behavioral suppression after NMDA was associated with nitric oxide from the inducible synthase. In a second series of experiments, comparable behavioral suppression by 0.1 mg/kg MK-801, but not 3 mg/kg phencyclidine, was attenuated by nitroprusside, molsidomine, and L-arginine, suggesting that suppressions from MK-801 and phencyclidine were mediated by different final common pathways, and that behavioral suppression from MK-801, but not phencyclidine, may be associated with Ca(2+)-dependent nitric oxide.


Asunto(s)
Condicionamiento Operante/efectos de los fármacos , Combinación de Medicamentos , Ácido Gálico/análogos & derivados , Ácido Quinurénico/análogos & derivados , Donantes de Óxido Nítrico/farmacocinética , Receptores de N-Metil-D-Aspartato/agonistas , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores , 2-Amino-5-fosfonovalerato/antagonistas & inhibidores , Animales , Arginina/administración & dosificación , Arginina/farmacocinética , Maleato de Dizocilpina/administración & dosificación , Maleato de Dizocilpina/farmacocinética , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Ácido Gálico/administración & dosificación , Ácido Gálico/farmacocinética , Guanidinas/administración & dosificación , Guanidinas/farmacocinética , Indazoles/administración & dosificación , Indazoles/farmacocinética , Inyecciones Intraperitoneales , Ácido Quinurénico/administración & dosificación , Ácido Quinurénico/farmacocinética , Molsidomina/administración & dosificación , Molsidomina/farmacocinética , N-Metilaspartato/administración & dosificación , N-Metilaspartato/antagonistas & inhibidores , N-Metilaspartato/farmacocinética , NG-Nitroarginina Metil Éster/administración & dosificación , NG-Nitroarginina Metil Éster/farmacocinética , Donantes de Óxido Nítrico/administración & dosificación , Óxido Nítrico Sintasa/administración & dosificación , Óxido Nítrico Sintasa/antagonistas & inhibidores , Óxido Nítrico Sintasa/farmacocinética , Óxido Nítrico Sintasa de Tipo II , Nitroprusiato/administración & dosificación , Nitroprusiato/farmacocinética , Fenciclidina/administración & dosificación , Fenciclidina/farmacocinética , Piperidinas/administración & dosificación , Piperidinas/farmacocinética , Ratas , Ratas Sprague-Dawley , Receptores de N-Metil-D-Aspartato/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA